Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo. - Wikidata - wikimedia - TriplyDB

Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo.

Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo.

http://www.wikidata.org/entity/Q34044910

about

Clinical manufacturing of CAR T cells: foundation of a promising therapy Different Subsets of T Cells, Memory, Effector Functions, and CAR-T Immunotherapy CAR T Cell Therapy: A Game Changer in Cancer Treatment Improving Adoptive T Cell Therapy: The Particular Role of T Cell Costimulation, Cytokines, and Post-Transfer Vaccination Clinical development of anti-CD19 chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma.Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults Driving CAR T-cells forward Bispecific antibodies and CARs: generalized immunotherapeutics harnessing T cell redirection.Targeting the adenosine 2A receptor enhances chimeric antigen receptor T cell efficacy Fully human CD19-specific chimeric antigen receptors for T-cell therapy.CD62L+ NKT cells have prolonged persistence and antitumor activity in vivo.CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients Augmentation of CAR T-cell Trafficking and Antitumor Efficacy by Blocking Protein Kinase A Localization.CD19-targeted CAR T-cell therapeutics for hematologic malignancies: interpreting clinical outcomes to date.Role of memory T cell subsets for adoptive immunotherapy.Allogeneic CD19-CAR-T cell infusion after allogeneic hematopoietic stem cell transplantation in B cell malignancies.Fast Cars and No Brakes: Autologous Stem Cell Transplantation as a Platform for Novel Immunotherapies.Novel Immunotherapies for Multiple Myeloma.Methods of ex vivo expansion of human cord blood cells: challenges, successes and clinical implications.Chimeric antigen receptor-engineered natural killer and natural killer T cells for cancer immunotherapy.Generation of clinical-grade CD19-specific CAR-modified CD8+ memory stem cells for the treatment of human B-cell malignancies.Driving gene-engineered T cell immunotherapy of cancer.Hematology oncology practice in the Asia-Pacific APHCON survey results from the 6th international hematologic malignancies conference: bridging the gap 2015, Beijing, China.Phase I Escalating-Dose Trial of CAR-T Therapy Targeting CEA+ Metastatic Colorectal Cancers.Chimeric antigen receptors: driving immunology towards synthetic biology.Chimeric Antigen Receptor T cells for B Cell Neoplasms: Choose the Right CAR for You.Review: Current clinical applications of chimeric antigen receptor (CAR) modified T cells.Chimeric Antigen Receptor T Cells and Hematopoietic Cell Transplantation: How Not to Put the CART Before the Horse.Chimeric Antigen Receptor (CAR) T Cells: Lessons Learned from Targeting of CD19 in B-Cell Malignancies.CD19-Targeted CAR T cells as novel cancer immunotherapy for relapsed or refractory B-cell acute lymphoblastic leukemia.Chimeric antigen receptor engineered stem cells: a novel HIV therapy.CARs: Synthetic Immunoreceptors for Cancer Therapy and Beyond.Engineering Chimeric Antigen Receptor T-Cells for Racing in Solid Tumors: Don't Forget the Fuel Chimeric Antigen Receptors: A Cell and Gene Therapy Perspective.Current status and perspectives of chimeric antigen receptor modified T cells for cancer treatment.Hit-and-run programming of therapeutic cytoreagents using mRNA nanocarriers.Isolation and functional characterization of hepatitis B virus-specific T-cell receptors as new tools for experimental and clinical use.The Multi-Purpose Tool of Tumor Immunotherapy: Gene-Engineered T Cells.Comprehensive Approach for Identifying the T Cell Subset Origin of CD3 and CD28 Antibody-Activated Chimeric Antigen Receptor-Modified T Cells.Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection.

P2860

Q26747037-7D5BBA24-222D-4DB4-935C-0B8A4C166839 Q26752955-74870241-7BC5-4C8A-8BF4-42F46F7F90AF Q26822769-D061E1A1-2938-47B0-99E5-CBD8CB14AEAF Q28068378-82E0F0D2-3A94-45F3-910D-390EE0937B70 Q33823270-E58270AC-3CE9-48B3-AC77-D5D3C89808BA Q33827997-344041EA-3988-4BA2-973F-155521F96865 Q34046505-72956122-4991-4D1D-B3FB-915057B038C3 Q34517676-FC75A166-0A5B-4E48-ACD7-6914ED47149C Q34550649-771C2EF3-8881-4EF5-AFF3-AFB5459CBDF3 Q36281920-32EA6B4F-B3C5-43F1-B9C9-34B000485C3C Q36951719-B9A4A938-181D-4CF2-980C-48C09B6C259F Q36951727-5B09ED28-ECB1-48B6-8E1E-F44093DC5825 Q36963494-0950EACE-BF87-4417-9E77-6B5159DA9EA7 Q37058098-B8E094FB-FCB6-427C-945F-D2709976C4DC Q37263366-8BE4903D-1040-414F-8647-AFB1E3CF436C Q37615772-C875BC3A-67B0-4481-B67C-5B2983B67C73 Q38612233-E37E860D-27CA-4263-AA68-A886A21E1E85 Q38640444-8C53795E-45BB-4783-98EB-E1990D145A13 Q38658670-4C596F28-8E40-4515-9F7B-5EFD1386B314 Q38666579-C94DFE1B-55AD-41FB-8F50-D6864BFAC9F8 Q38768392-FEBC78CD-7260-4A1F-AC7A-27585F9AB938 Q38777742-0A7240E4-E338-4F17-BA1A-8256B755421E Q38839367-F9B5555D-628B-443C-9C3C-C2D96FBE9E70 Q38861769-6E9C4773-532D-4D47-B8F8-10163F593746 Q38884383-1372BBC0-A2A8-4B40-B113-07597231E9F1 Q38913549-79CA781C-30F8-4403-A182-A3E978F4DE1F Q38945853-5FD2CA71-2BA5-41E5-BE96-3713F04EFCB9 Q38957129-DF69743C-BD9E-4355-9502-2040729C63DC Q39007364-9F37A199-B96A-4953-A588-48736109B6C7 Q39032901-93FF6FD8-D0E1-496F-81FC-2F646D4662AF Q39208504-8A9AE654-42C5-4315-AC8C-E17FF4D21437 Q39246685-133A9771-795D-4147-9D04-58D07F2EF472 Q39249589-9B1AB138-83CA-4015-B9DC-C27BB36AA4FD Q39272183-F894F459-A7BB-4768-BFF6-5B3EEB129AA2 Q39280002-9AA3422F-AA94-4852-8404-ABA87C1331A2 Q40064246-4CFF7C18-6A81-4560-A215-D5145E4D3D4D Q40089302-E0BAC35E-DA89-4F90-8F64-3756EFE49956 Q40095245-FF9997DC-0B62-4581-80F0-4287C7EB1B2B Q40183378-ACBD1C46-A6BD-40B9-AC15-475191D70CF9 Q40323802-6E32DB7B-96E8-4C41-99E1-A9D5BC0C4C07

P2860

Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo.

http://www.wikidata.org/entity/Q34044910

description

2015 nî lūn-bûn

@nan

2015 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

name

Chimeric antigen receptor-modi ...... antitumor reactivity in vivo.

@ast

Chimeric antigen receptor-modi ...... antitumor reactivity in vivo.

@en

Chimeric antigen receptor-modi ...... antitumor reactivity in vivo.

@nl

type

label

Chimeric antigen receptor-modi ...... antitumor reactivity in vivo.

@ast

Chimeric antigen receptor-modi ...... antitumor reactivity in vivo.

@en

Chimeric antigen receptor-modi ...... antitumor reactivity in vivo.

@nl

prefLabel

Chimeric antigen receptor-modi ...... antitumor reactivity in vivo.

@ast

Chimeric antigen receptor-modi ...... antitumor reactivity in vivo.

@en

Chimeric antigen receptor-modi ...... antitumor reactivity in vivo.

@nl

P1433

Q34044910-9EA8AF48-AA66-4100-8018-F9239DF4AD59

P1476

Q34044910-E0931CEF-F4AB-4695-BDE9-6C26E5C73BB0

P2093

Q34044910-0834E876-E5DC-40E0-97D7-6F5E61A745F3

Q34044910-3F5D7868-D0E3-49D4-B471-6FFCE9331DC6

Q34044910-4444E9FD-9FAE-4F2A-A2B2-452D92BF8D53

Q34044910-7EDF34FD-694E-49BF-B3DC-6D037D5CB4EE

Q34044910-C1863B59-7CDF-4B47-AD48-003B61605377

Q34044910-C5BC106A-AEDE-4A5D-9AC4-2C64C9059FC4

P2860

Q34044910-07A27953-4EE8-46AA-A1BC-FA58B4ACF2DE

Q34044910-2553DC4F-16B6-4C85-8425-023BBC5A0EAC

Q34044910-2625CD6E-A999-4FE7-A30B-96D3A2EC3CAC

Q34044910-275B3FAF-ACE6-4585-AD62-2A7772498BC2

Q34044910-29203CA2-5D77-4FB6-A31C-1B210D52D5BB

Q34044910-2AF11AC9-C03F-4D05-83FF-0BC09D7801A4

Q34044910-2CE2F65A-53F1-479B-BAD4-70E7584D0C00

Q34044910-373D14D7-F77B-4D23-B466-0C31315B40D7

Q34044910-3D09F30E-A87B-4866-B958-73445617EA28

Q34044910-3FB23ABD-5AEC-405F-B033-1DDA0EF7E3CA

P2888

Q34044910-AF65AE0A-B6AB-43CD-84FA-D00CD1A2BA26

P304

Q34044910-36EB83C9-C352-4AAD-8BCF-7AB1E63541E3

P31

Q34044910-59450CFC-8A7A-45D5-BA5A-9AE1D764939D

P356

Q34044910-3153A042-B2BC-4FEF-AAA6-14AD80C02278

P433

Q34044910-5D281535-BC3D-48E3-ADF8-CB11E17C8BAA

P478

Q34044910-A22D5515-8394-4581-BFB1-1F2559239931

P50

Q34044910-3BBF7676-8410-475B-A89B-65B6116FE7A5

P577

Q34044910-834944A4-1C76-4397-861E-068DDB0FE61C

P6179

Q34044910-C25EB24C-C541-4598-BFB1-0F8A7B1FB79C

P698

Q34044910-24E91317-ACCF-4189-A444-2FA727BABEA7

P932

Q34044910-175ECE43-D649-4FEC-B900-01CB8ED97D33

P356

P1433

P1476

Chimeric antigen receptor-modi ...... antitumor reactivity in vivo.

@en

P2093

C J Turtle

http://www.w3.org/2001/XMLSchema#string

D G Maloney

http://www.w3.org/2001/XMLSchema#string

D Sommermeyer

http://www.w3.org/2001/XMLSchema#string

P L Kosasih

http://www.w3.org/2001/XMLSchema#string

S R Riddell

http://www.w3.org/2001/XMLSchema#string

T Gogishvili

http://www.w3.org/2001/XMLSchema#string

P2860

Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells

Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia

T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia

Wnt signaling arrests effector T cell differentiation and generates CD8+ memory stem cells

A human memory T cell subset with stem cell-like properties

Novel serial positive enrichment technology enables clinical multiparameter cell sorting

Chimeric antigen receptor T cells for sustained remissions in leukemia

Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia

Chimeric antigen receptor-modified T cells for acute lymphoid leukemia

B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells

P2888

P304

492-500

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/LEU.2015.247

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

30

http://www.w3.org/2001/XMLSchema#string

P50

Michael Hudecek

P577

2015-09-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1050157516

http://www.w3.org/2001/XMLSchema#string

P698

26369987

http://www.w3.org/2001/XMLSchema#string

P932

4746098

http://www.w3.org/2001/XMLSchema#string